A2 Biotherapeutics, Inc. Secures $57 Million USD in a Series A Funding Round


(Agoura Hills, CA) Just recently in history, A2 Biotherapeutics, Inc. emerged out of stealth mode.  Fascinatingly, it was in stealth mode since the year 2018; when this business was founded.  The founders were ex-employees of Amgen, Inc.  The previous, is an American multinational biopharmaceutical business.  It is commonly known as the proprietor of immunostimulator medication, which is used to prevent infections in patients, who are undergoing cancer chemotherapy treatment.  Therefore and as a result, early in the stealth mode stage, A2 Biotherapeutics, Inc. became infused with a deep passion for cancer research.  Since the emergence out of stealth mode, A2 Biotherapeutics, Inc. has become the proud proprietor, of a technology platform.  The A2 Biotherapeutics’ technology platform aims at the development of a pipeline, of selective tumor cell therapeutics.  Recently, A2 Biotherapeutics, Inc. announced that, it desires to develop innovative cell therapies for cancer patients.  Specifically, the aforementioned business revealed that, it has secured $57 million USD in a Series A funding round.  The most noteworthy new investors of the aforementioned business are The Column Group, Vida Ventures, Samsara Bio Capital and Nextech Invest. 
            Nextech Invest, Samsara Bio Capital, Vida Ventures and The Column Group as the most noteworthy new investors; will be contributing funds.  The funds will be used for the following one thing.  The one thing is the continuation of the business launch.  In reference to, the continuation of the business launch, the aforementioned involves advancing the product candidates.  In order to accomplish this task, the funds will pay for a fully integrated discovery, development and manufacturing facility.  The facility, in turn, will house the organization of the business.  Additionally and currently, the organization employs more than 40 staff members.  In other words, A2 Biotherapeutics, Inc. is going to finish building up and launching. 
            However and returning to, A2 Biotherapeutics’ technology platform, the aforementioned is made possible by licensed technology.  The licensed technology is from Innovative Targeting Solutions.  This business has its headquarters office in Vancouver, the Country of Canada.  Specifically, and what the technology platform does, is identify rare binders.  These rare binders are derived from antibodies, T.C.R.s, precision binder engineering, precision binder optimization and binder modular design.  Helping the technology platform, are A2 Biotherapeutics’ proprietary binders.  A2 Biotherapeutics’ binders are antibody fragments, and, T.C.R. fragments that; bind to the targeted cancer cells.  Overall, A2 Biotherapeutics’ technology platform is highlighted by the following four things.  The first thing; it determines the content of T cell proliferation, cytotoxicity and survival.  For survival, it means acutely or over time.  The second thing, it is able to enrich the binders.  The goal is to optimize the binders’ most important parameters, in regards to cell therapy.  The third thing, it is able to process modular constructs.  The goal is to integrate multiple signals, in order, to provide a large therapeutic window.  The fourth thing, it has two major types of signal integration.  The first type is a molecular integrator that, has a single bispecific molecule.  The second type is a cellular integrator that, has two independent modules.
            To end, A2 Biotherapeutics, Inc. did release press statements.  Madhu Balachandran is a Member of A2 Biotherapeutics’ Board of Directors.  Through a press statement, Ms./Mrs. Balachandran said the following.  “A2 Biotherapeutics aspires to increase speed to patients and reduce cost of goods by leveraging its cell therapy manufacturing expertise and advances in technology.”  Scott Foraker is the President and the Chief Executive Officer of A2 Biotherapeutics, Inc.  Through a press statement, Mr. Foraker said the following.  “Our unique approach to targeted killing of tumor cells has the potential to create breakthrough cancer therapies that we look forward to bringing to patients, particularly those in need of new approaches.”  Alexander Kamb is a Co-Founder and the Chief Scientific Officer of A2 Biotherapeutics, Inc.  Through a press statement, Mr. Kamb said the following.  “This approach has the promise of being utilized for multiple tumor types, providing solutions for many cancer patients.  A2 Biotherapeutics has potent, highly selective binders that we combine into molecular constructs to integrate multiple signals and potentially provide a large therapeutic window.”  As previously stated, A2 Biotherapeutics, Inc. recently announced that, it desires to develop innovative cell therapies for cancer patients.  Specifically, the aforementioned business revealed that, it has secured $57 million USD in a Series A funding round.  Lastly; the most noteworthy new investors of the aforementioned business are The Column Group, Vida Ventures, Samsara Bio Capital and Nextech Invest. 

###
Written from Press Release
Registered Writer with
PR Newswire Association, LLC
R-Berumen28
11/09/2019

To Purchase Newspaper/Magazine Articles from this Author,
Please Use this Link:

To Read Exclusive and Only-Subscriber Articles,
Please Use this Link to Coil.com:


Post a Comment

Previous Post Next Post